clinicaloncologyКлинический случай в онкологииClinical Case in Oncology3034-14773034-4018ОНКОПРАКТИК10.62546/3034-1477-2024-2-2-39-47clinicaloncology-38Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCASE REPORTSЖизнеугрожающие осложнения иммунотерапии: синдром Стивенса-Джонсона и токсический эпидермальный некролизLife-threating complications of immunotherapy: Stevens-Johnson syndrome and toxic epidermal necrolysisТесленкоК. Н.TeslenkoK. N.

Тесленко Ксения Николаевна — врач-онколог онкологического химиотерапевтического отделения (противоопухолевой лекарственной терапии) № 13

193318, Санкт-Петербург, пр. Ветеранов, д. 56 

Teslenko Ksenia Nikolaevna — Oncologist, Department of Antitumor Drug Therapy No. 13 

56, Veteranov Ave., St. Petersburg, 193318 

teslenkoksenia@mail.ruОрловаР. В.OrlovaR. V.

Орлова Рашида Вахидовна — доктор медицинских наук, профессор, заведующий кафедрой онкологии; главный специалист по клинической онкологии 

199106, Санкт-Петербург, 21-линия В.О., д. 8а 

193318, Санкт-Петербург, пр. Ветеранов, д. 56 

Orlova Rashida Vakhidovna — Doctor of Medical Sciences, Prof., Head. Department of Oncology; Ch. clinical oncology specialist

St. Petersburg 

orlova_rashida@mail.ruФГБОУ ВО «Санкт-Петербургский государственный университет»РоссияSt. Petersburg State UniversityRussian FederationСПб ГБУЗ «Городской клинический онкологический диспансер» ; ФГБОУ ВО «Санкт-Петербургский государственный университет»РоссияCity Clinical Oncology Dispensary ; St. Petersburg State UniversityRussian Federation202417102024223947Copyright © Тесленко К.Н., Орлова Р.В., 20242024Тесленко К.Н., Орлова Р.В.Teslenko K.N., Orlova R.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncocase.ru/jour/article/view/38

Синдром Стивенса–Джонсона (ССД) и токсический эпидермальный некролиз (ТЭН) — угрожающие жизни состояния, сопровождающиеся поражением кожи, а также в некоторых случаях слизистых оболочек, проявляющиеся некрозом и отслойкой эпидермиса. Эти состояния относятся к неотложным и требуют экстренной госпитализации в стационар. Наиболее часто данные состояния развиваются при приеме лекарственных препаратов, однако в некоторых случаях причину заболевания выяснить не удается. В описанном случае мы столкнулись с данным состоянием у пациента, который получал иммунотерапию препаратом пембролизумаб — моноклональным антителом к рецептору PD-1, который в настоящее время широко используется в лечении пациентов онкологического профиля.

Stevens–Johnson syndrome (SSD) and toxic epidermal necrolysis (TEN) are life–threatening conditions accompanied by skin lesions, as well as in some cases mucous membranes, manifested by necrosis and detachment of the epidermis. These conditions are considered urgent and require emergency hospitalization. Most often, these conditions develop when taking drugs, but in some cases it is not possible to find out the cause of the disease. In described case, we discovered this condition in a patient, who received immunotherapy with pembrolizumab, a monoclonal antibody to the PD-1 receptor, which generally used in the treatment of cancer patients.

синдром Стивенса–Джонсонатоксический эпидермальный некролизсиндром Лайеллаингибиторы контрольных точеккожная токсичностьиммуноопосредованные нежелательные явленияпембролизумабStevens–Johnson syndrometoxic epidermal necrolysisLyell’s syndromecheckpoint inhibitorscutaneous toxicityimmuno-related adverse eventspembrolizumabReferencesDuong T.A., Valeyrie-Allanore L., Wolkenstein P., Chosidow O. Severe cutaneous adverse reactions to drugs // Lancet. 2017. Oct 28; Vol. 390, No. 10106. Р. 1996–2011. doi: 10.1016/S0140-6736(16)30378-6. Epub 2017 May 2.Duong T.A., Valeyrie-Allanore L., Wolkenstein P., Chosidow O. Severe cutaneous adverse reactions to drugs // Lancet. 2017. Oct 28; Vol. 390, No. 10106. Р. 1996–2011. doi: 10.1016/S0140-6736(16)30378-6. Epub 2017 May 2.Bastuji-Garin S. et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme // Arch. Dermatol. 1993. Vol. 129. P. 92–96.Bastuji-Garin S. et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme // Arch. Dermatol. 1993. Vol. 129. P. 92–96.Hsu D., Brieva J., Silverberg N.B., Silverberg J. Morbidity and Mortality of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults // J. Invest. Dermatol. 2016. Jul; Vol. 136, No. 7. Р. 1387–1397. doi: 10.1016/j.jid.2016.03.023. Epub 2016 Mar 30.Hsu D., Brieva J., Silverberg N.B., Silverberg J. Morbidity and Mortality of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults // J. Invest. Dermatol. 2016. Jul; Vol. 136, No. 7. Р. 1387–1397. doi: 10.1016/j.jid.2016.03.023. Epub 2016 Mar 30.Yang M.-S., Lee J.Y., Kim J., Kim G.-W., Kim B.-K., Kim J.-Y., Park H.-W., Cho S.-H., Min K.-U., Kang H.-R. Incidence of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea // PLoS One. 2016. Nov 11; Vol. 11, No, 11. e0165933. doi: 10.1371/journal.pone.0165933. eCollection 2016.Yang M.-S., Lee J.Y., Kim J., Kim G.-W., Kim B.-K., Kim J.-Y., Park H.-W., Cho S.-H., Min K.-U., Kang H.-R. Incidence of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea // PLoS One. 2016. Nov 11; Vol. 11, No, 11. e0165933. doi: 10.1371/journal.pone.0165933. eCollection 2016.Charlton O.A., Harris V., Phan K., Mewton E., Jackson C., Cooper A. Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review // Adv. Wound Care. 2020. Vol. 9. Р. 426–439.Charlton O.A., Harris V., Phan K., Mewton E., Jackson C., Cooper A. Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review // Adv. Wound Care. 2020. Vol. 9. Р. 426–439.Shanbhag S., Chodosh J., Fathy C., Goverman J., Mitchell C., Saeed H.N. Multidisciplinary care in Stevens–Johnson syndrome // Ther. Adv. Chronic Dis. 2020. Vol. 11.Shanbhag S., Chodosh J., Fathy C., Goverman J., Mitchell C., Saeed H.N. Multidisciplinary care in Stevens–Johnson syndrome // Ther. Adv. Chronic Dis. 2020. Vol. 11.Gregory D.G. New Grading System and Treatment Guidelines for the Acute Ocular Manifestations of Stevens– Johnson Syndrome // Ophthalmology. 2016. Vol. 123. Р. 1653–1658.Gregory D.G. New Grading System and Treatment Guidelines for the Acute Ocular Manifestations of Stevens– Johnson Syndrome // Ophthalmology. 2016. Vol. 123. Р. 1653–1658.Meneux E. et al. Vulvovaginal sequelae in toxic epidermal necrolysis // J. Reprod. Med. 1997. Vol. 42. P. 153–156.Meneux E. et al. Vulvovaginal sequelae in toxic epidermal necrolysis // J. Reprod. Med. 1997. Vol. 42. P. 153–156.Lebargy F., Wolkenstein P., Gisselbrecht M. et al. Pulmonary complications in toxic epidermal necrolysis: Prospective clinical study // Intensive Care Med. 1997. Vol. 23. Р. 1237–1244.Lebargy F., Wolkenstein P., Gisselbrecht M. et al. Pulmonary complications in toxic epidermal necrolysis: Prospective clinical study // Intensive Care Med. 1997. Vol. 23. Р. 1237–1244.Bastuji-Garin S., Fouchard N., Bertocchi M. et al. SCORTEN: A severity-of illness score for toxic epidermal necrolysis // J. Invest. Dermatol. 2000. Vol. 115. Р. 149–153.Bastuji-Garin S., Fouchard N., Bertocchi M. et al. SCORTEN: A severity-of illness score for toxic epidermal necrolysis // J. Invest. Dermatol. 2000. Vol. 115. Р. 149–153.Noe M.H., Rosenbach M., Hubbard R.A., Mostaghimi A., Cardones A.R., Chen J.K., Cotliar J., Davis M.D.P., Dominguez A., Fox L.P. et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients with Stevens–Johnson Syndrome/Toxic Epidermal Necroly-sis-ABCD-10 // JAMA Dermatol. 2019. Vol. 155. Р. 448–454.Noe M.H., Rosenbach M., Hubbard R.A., Mostaghimi A., Cardones A.R., Chen J.K., Cotliar J., Davis M.D.P., Dominguez A., Fox L.P. et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients with Stevens–Johnson Syndrome/Toxic Epidermal Necroly-sis-ABCD-10 // JAMA Dermatol. 2019. Vol. 155. Р. 448–454.Charlton O.A., Harris V., Phan K., Mewton E., Jackson C., Cooper A. Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review // Adv. Wound Care. 2020. Vol. 9. Р. 426–439.Charlton O.A., Harris V., Phan K., Mewton E., Jackson C., Cooper A. Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review // Adv. Wound Care. 2020. Vol. 9. Р. 426–439.Sassolas B., Haddad C., Mockenhaupt M., Dunant A., Liss Y., Bork K., Haustein U.F., Vieluf D., Roujeau J.C., Le Louet H. et al. ALDEN, an algorithm for assessment of drug causal-ity in stevens-johnson syndrome and Toxic Epidermal Necrolysis: Comparison with case-control analysis // Clin. Pharmacol. Ther. 2010. Vol. 88. Р. 60–68.Sassolas B., Haddad C., Mockenhaupt M., Dunant A., Liss Y., Bork K., Haustein U.F., Vieluf D., Roujeau J.C., Le Louet H. et al. ALDEN, an algorithm for assessment of drug causal-ity in stevens-johnson syndrome and Toxic Epidermal Necrolysis: Comparison with case-control analysis // Clin. Pharmacol. Ther. 2010. Vol. 88. Р. 60–68.Hasegawa A., Abe R. Recent advances in managing and understanding Stevens–Johnson syndrome and Toxic Epidermal Necrolysis // F1000Research. 2020. Vol. 9. Р. 612.Hasegawa A., Abe R. Recent advances in managing and understanding Stevens–Johnson syndrome and Toxic Epidermal Necrolysis // F1000Research. 2020. Vol. 9. Р. 612.Abe R. Immunological response in Stevens–Johnson syndrome and Toxic Epidermal Necrolysis // J. Dermatol. 2015. Vol. 42. Р. 42–48.Abe R. Immunological response in Stevens–Johnson syndrome and Toxic Epidermal Necrolysis // J. Dermatol. 2015. Vol. 42. Р. 42–48.Paulmann M., Mockenhaupt M. Severe skin reactions: Clinical picture, epidemiology, etiology, pathogenesis, and treatment // Allergo J. Int. 2019. Vol. 28. Р. 311–326.Paulmann M., Mockenhaupt M. Severe skin reactions: Clinical picture, epidemiology, etiology, pathogenesis, and treatment // Allergo J. Int. 2019. Vol. 28. Р. 311–326.Барденикова С.И., Пеньтковская О.С., Исаева Е.К. Синдром Стивенса–Джонсона — иммунная катастрофа // РМЖ. Мать и дитя. 2019. Т. 2, № 1. С. 66–72. doi: 10.32364/2618–8430-2019-2-1-66-72.Bardenikova S.I., Pentkovskaya O.S., Isaeva E.K. Stevens–Johnson syndrome — an immune catastrophe. Russian Medical Journal. Mother and child, 2019, Vol. 2, No. 1, рр. 66–72 (In Russ.). doi: 10.32364/2618–8430-2019-2-1-66-72.Jaller J.A., McLellan B.N., Balagula Y. Wound Management in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis // Curr. Dermatol. Rep. 2020. Vol. 9. Р. 58–72.Jaller J.A., McLellan B.N., Balagula Y. Wound Management in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis // Curr. Dermatol. Rep. 2020. Vol. 9. Р. 58–72.Chafranska L., Saunte D.M., Behrendt N., Nygaard U., Christensen R.J., Sand C., Jemec G.B. Pediatric Toxic Epidermal Necrolysis treated successfully with infliximab // Pediatric Dermatol. 2019. Vol. 36. Р. 342–345.Chafranska L., Saunte D.M., Behrendt N., Nygaard U., Christensen R.J., Sand C., Jemec G.B. Pediatric Toxic Epidermal Necrolysis treated successfully with infliximab // Pediatric Dermatol. 2019. Vol. 36. Р. 342–345.Wang R., Zhong S., Tu P., Li R., Wang M. Rapid remission of Stevens–Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature // Dermatol. Ther. 2019. Vol. 32. e12832.Wang R., Zhong S., Tu P., Li R., Wang M. Rapid remission of Stevens–Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature // Dermatol. Ther. 2019. Vol. 32. e12832.Sanlorenzo M., Vujic I., Daud A., Algazi A., Gubens M., Luna S.A. et al. Pembrolizumab cutaneous adverse events and their association with disease progression // JAMA Dermatol. 2015. Nov; Vol. 151, No. 11. Р. 1206–1212.Sanlorenzo M., Vujic I., Daud A., Algazi A., Gubens M., Luna S.A. et al. Pembrolizumab cutaneous adverse events and their association with disease progression // JAMA Dermatol. 2015. Nov; Vol. 151, No. 11. Р. 1206–1212.Goldinger S.M., Stieger P., Meier B., Micaletto S., Contassot E., French L.E. et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy // Clin. Cancer Res. 2016. Mar; Vol. 22, Nо. 16. Р. 4023–4029.Goldinger S.M., Stieger P., Meier B., Micaletto S., Contassot E., French L.E. et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy // Clin. Cancer Res. 2016. Mar; Vol. 22, Nо. 16. Р. 4023–4029.Maloney N.J., Ravi V., Cheng K., Bach D.Q., Worswick S. Stevens–Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review // Int. J. Dermatol. 2020. Jun; Vol. 59, Nо. 6. e183-e188.Maloney N.J., Ravi V., Cheng K., Bach D.Q., Worswick S. Stevens–Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review // Int. J. Dermatol. 2020. Jun; Vol. 59, Nо. 6. e183-e188.Aoyama R., Kondo Y., Azuma N., Kira M. Toxic epidermal necrolysis as a complication of pembrolizumab treatment in a lung cancer patient // J. Cutan. Immunol. Allergy. 2020. Nov; Vol. 4, Nо. 2. Р. 41–42. [Google Scholar]Aoyama R., Kondo Y., Azuma N., Kira M. Toxic epidermal necrolysis as a complication of pembrolizumab treatment in a lung cancer patient // J. Cutan. Immunol. Allergy. 2020. Nov; Vol. 4, Nо. 2. Р. 41–42. [Google Scholar]Robinson S., Saleh J., Curry J., Mudaliar K. Pembrolizumab-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in a patient with metastatic cervical squamous cell carcinoma: a case report // Am. J. Dermatopathol. 2020. Apr; Vol. 42, Nо. 4. Р. 292–296.Robinson S., Saleh J., Curry J., Mudaliar K. Pembrolizumab-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in a patient with metastatic cervical squamous cell carcinoma: a case report // Am. J. Dermatopathol. 2020. Apr; Vol. 42, Nо. 4. Р. 292–296.Borg L., Buhagiar M., La Ferla E., Pisani D., Said J., Boffa M.J. Pembrolizumab-Induced Toxic Epidermal Necrolysis // Case Rep. Oncol. 2022. Oct 3; Vol. 15, Nо. 3. Р. 887–893.Borg L., Buhagiar M., La Ferla E., Pisani D., Said J., Boffa M.J. Pembrolizumab-Induced Toxic Epidermal Necrolysis // Case Rep. Oncol. 2022. Oct 3; Vol. 15, Nо. 3. Р. 887–893.

The authors declare that there are no conflicts of interest present.